News

Gilead Sciences Inc. Chief Executive Officer Daniel O’Day said the company’s new HIV prevention drug Yeztugo should be able ...
Patients with HIV who are resistant to all four antiretroviral drug classes face a higher risk for death than those who are ...
I n July, Meghalaya Health and Family Welfare Minister Mazel Ampareen Lyngdoh announced that the State may follow Goa in ...
The HIV epidemic in the Philippines continues to escalate, with new cases increasing by 500 percent over the past decade.
The two-month campaign will follow a weekly thematic approach covering 8 themes across 200 villages, 400 schools, 86 colleges ...
When it comes to HIV prevention, the U.S. Supreme Court appeared to back up the task force with its July 11 ruling in Kennedy ...
With Black women and straight men increasingly at risk, Gilead’s Yeztugo may finally offer a discreet, stigma-free way to stop the spread of HIV before the system fails them.
THE European Medicines Agency on Friday recommended authorizing a twice-yearly injectable drug “lenacapavir” to prevent HIV and help end the virus’ transmission.
Kenya is one of nine African countries selected for the initial rollout of lenacapavir (LEN), a new injectable drug for human ...
Opinion: By dismantling proven HIV prevention and overdose reduction programs, the Trump administration is replacing science ...
Why an HIV patient advocacy group is suing the Trump administration over a Biden administration legal settlement with Gilead ...
Analysts lift targets for Gilead as HIV sales surge and Yeztugo launch gains traction, supporting a stronger full-year ...